UBS Maintains Buy on Cardinal Health, Raises Price Target to $280

Benzinga Newsdesk www.benzinga.com Positive 84.8%

Neg 0% Neu 0% Pos 84.8%

UBS analyst Kevin Caliendo maintains Cardinal Health (NYSE:CAH) with a Buy and raises the price target from $274 to $280.